ArticleMolecules (Basel, Switzerland)2014
Design and synthesis of chalcone derivatives as inhibitors of the ferredoxin - ferredoxin-NADP+ reductase interaction of Plasmodium falciparum: pursuing new antimalarial agents.
Article in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 64 citations in OpenAlex.
- Diastereoselective synthesis of novel (S)-lactic pyrazoline derivatives and investigation of antibacterial capabilities.Scientific reports · 2025Article
- Article
- Article
- Review
- Chalcones as Anti-Glioblastoma Stem Cell Agent Alone or as Nanoparticle Formulation Using Carbon Dots as Nanocarrier.Pharmaceutics · 2022Article
- In vitro and in silico assessment of new beta amino ketones with antiplasmodial activity.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Roles of Ferredoxin-Dependent Proteins in the Apicoplast of Plasmodium falciparum Parasites.mBio · 2021Article
- Design, Synthesis, Characterization and in vivo Antidiabetic Activity Evaluation of Some Chalcone Derivatives.Drug design, development and therapy · 2021Article
- C3 amino-substituted chalcone derivative with selective adenosineChemicke zvesti · 2021Article
- Reactions ofInternational journal of molecular sciences · 2020Article
- Synthesis andRSC advances · 2020Article
- Synthesis and Biological Evaluation of Novel Aminochalcones as Potential Anticancer and Antimicrobial Agents.Molecules (Basel, Switzerland) · 2019Article
- Article
- Design and Synthesis of Benzimidazole-Chalcone Derivatives as Potential Anticancer Agents.Molecules (Basel, Switzerland) · 2019Article
- Inhibitory Activity and Docking Analysis of Antimalarial Agents fromJournal of parasitology research · 2018Article
- Comparison of various synthesis methods and synthesis parameters of pyrazoline derivates.Journal of advanced pharmaceutical technology & researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some chalcones have been designed and synthesized using Claisen-Schmidt reactions as inhibitors of the ferredoxin and ferredoxin-NADP+ reductase interaction to pursue a new selective antimalaria agent. The synthesized compounds exhibited inhibition interactions between PfFd-PfFNR in the range of 10.94%-50%. The three strongest inhibition activities were shown by (E)-1-(4-aminophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (50%), (E)-1-(4-aminophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one (38.16%), and (E)-1-(4-aminophenyl)-3-(2,3-dimethoxyphenyl)prop-2-en-1-one (31.58%). From the docking experiments we established that the amino group of the methoxyamino chlacone derivatives plays an important role in the inhibition activity by electrostatic interaction through salt bridges and that it forms more stable and better affinity complexes with FNR than with Fd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.